Share on StockTwits

Eli Lilly & Co. (NYSE:LLY)‘s stock had its “buy” rating reiterated by investment analysts at Sanford C. Bernstein in a note issued to investors on Tuesday, reports. They currently have a $61.00 price target on the stock. Sanford C. Bernstein’s price objective would indicate a potential upside of 16.35% from the company’s current price.

LLY has been the subject of a number of other recent research reports. Analysts at JPMorgan Chase & Co. raised their price target on shares of Eli Lilly & Co. (NYSE:LLY) from $59.00 to $61.00 in a research note to investors on Tuesday. They now have a “neutral” rating on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Eli Lilly & Co. (NYSE:LLY) in a research note to investors on Tuesday, September 3rd. They now have a $54.00 price target on the stock. Finally, analysts at Leerink Swann raised their price target on shares of Eli Lilly & Co. (NYSE:LLY) from $60.00 to $62.00 in a research note to investors on Wednesday, August 14th. They now have an “outperform” rating on the stock.

One analyst has rated the stock with a sell rating, eight have issued a hold rating and nine have assigned a buy rating to the stock. Eli Lilly & Co. has a consensus rating of “Hold” and a consensus target price of $57.47.

Shares of Eli Lilly & Co. (NYSE:LLY) traded down 1.15% on Tuesday, hitting $52.43. The stock had a trading volume of 5,359,035 shares. Eli Lilly & Co. has a 52-week low of $44.88 and a 52-week high of $58.40. The stock’s 50-day moving average is $52.94 and its 200-day moving average is $53.66. The company has a market cap of $56.635 billion and a P/E ratio of 11.91.

Eli Lilly & Co. (NYSE:LLY) last released its earnings data on Wednesday, July 24th. The company reported $1.16 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.01 by $0.15. The company had revenue of $5.93 billion for the quarter, compared to the consensus estimate of $5.82 billion. During the same quarter last year, the company posted $0.83 earnings per share. Eli Lilly & Co.’s revenue was up 5.9% compared to the same quarter last year. Analysts expect that Eli Lilly & Co. will post $4.14 EPS for the current fiscal year.

Eli Lilly and Company discovers, develops, manufactures, and sells products, in one business segment, pharmaceutical products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.